Quantbot Technologies LP Sells 21,601 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Quantbot Technologies LP cut its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 95.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,026 shares of the specialty pharmaceutical company's stock after selling 21,601 shares during the quarter. Quantbot Technologies LP's holdings in Supernus Pharmaceuticals were worth $32,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. GAMMA Investing LLC boosted its stake in shares of Supernus Pharmaceuticals by 97.1% during the 3rd quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company's stock worth $25,000 after acquiring an additional 398 shares in the last quarter. Meeder Asset Management Inc. acquired a new stake in shares of Supernus Pharmaceuticals in the second quarter worth $47,000. Innealta Capital LLC acquired a new stake in shares of Supernus Pharmaceuticals in the second quarter worth $51,000. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Supernus Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company's stock worth $61,000 after buying an additional 352 shares during the period. Finally, nVerses Capital LLC acquired a new stake in shares of Supernus Pharmaceuticals in the second quarter worth $72,000.

Analyst Ratings Changes

Several brokerages have recently commented on SUPN. Cowen reaffirmed a "buy" rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Piper Sandler reissued a "neutral" rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th.

Supernus Pharmaceuticals Stock Performance

Shares of Supernus Pharmaceuticals stock traded up $0.18 during trading on Friday, reaching $37.17. The company's stock had a trading volume of 220,367 shares, compared to its average volume of 327,726. The business's fifty day moving average price is $34.84 and its 200-day moving average price is $31.63. The firm has a market cap of $2.05 billion, a price-to-earnings ratio of 34.74 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a one year low of $25.53 and a one year high of $39.37.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last issued its earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 EPS for the quarter, topping the consensus estimate of $0.44 by $0.25. The firm had revenue of $175.70 million during the quarter, compared to analysts' expectations of $157.35 million. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. Supernus Pharmaceuticals's quarterly revenue was up 14.2% compared to the same quarter last year. During the same period last year, the business earned ($0.29) earnings per share. Sell-side analysts anticipate that Supernus Pharmaceuticals, Inc. will post 2.37 EPS for the current year.

Insider Activity at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, CEO Jack A. Khattar sold 125,000 shares of the company's stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $36.68, for a total value of $4,585,000.00. Following the sale, the chief executive officer now directly owns 926,172 shares in the company, valued at $33,971,988.96. This represents a 11.89 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Frank Mottola sold 15,000 shares of Supernus Pharmaceuticals stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $36.98, for a total value of $554,700.00. Following the transaction, the senior vice president now directly owns 8,200 shares of the company's stock, valued at approximately $303,236. The trade was a 64.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 154,213 shares of company stock valued at $5,660,180 over the last quarter. 9.30% of the stock is owned by company insiders.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.